Skip to main content
Caliway logo

Caliway — Investor Relations & Filings

Ticker · 6919 ISIN · TW0006919004 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 59 across all filing types
Latest filing 2026-06-05 Director's Dealing
Country TW Taiwan
Listing TW 6919

About Caliway

www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
115年05月內部人持股異動(事後)
Director's Dealing Classification · 92% confidence The document is a detailed table from the public MOPS (公開資訊觀測站) showing shareholdings, monthly increases and decreases, and trust/pledge status for company insiders (directors, executives, and their close relatives). It is not an announcement of a report publication, nor a general regulatory update; rather it is a periodic insider transaction and holdings disclosure. This matches the Director's Dealing category.
2026-06-05 Chinese
115年05月董事會成員及持股
Director's Dealing Classification · 85% confidence The document is a detailed insider shareholding disclosure showing company directors and executives’ ‘selected time’ and ‘current’ holdings plus pledged shares, consistent with insider transaction/holding reports. This matches the Director’s Dealing category (INSIDER DEALING) rather than a full financial report or other announcements.
2026-06-05 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之3b期 長期追蹤臨床試驗CBL-0303申請，今日已完成美國FDA送件
Regulatory Filings Classification · 82% confidence The document is a public market disclosure from Taiwan’s Market Observation Post System (MOPS), provided by listed company 6919 康霈, describing a clinical trial IND submission to the FDA for a new drug candidate. It is a mandatory regulatory announcement of a material event rather than an actual financial report, earnings release, or management presentation. This fits the “Regulatory Filings” (RNS) category as a general compliance announcement.
2026-06-03 Chinese
114年第4季股利金額(董事會決議)
Notice of Dividend Amount Classification · 89% confidence The document is a dividend distribution schedule (“公司股利分派情形”) showing board resolutions, shareholders’ meeting confirmations, per-share cash dividend amounts, record dates and related dividend policies. This matches a Notice of Dividend Amount rather than a full financial report or subsidiary filing. Thus it is classified as a dividend announcement.
2026-05-22 Chinese
公司治理組織架構
Governance Information Classification · 90% confidence The document is a table from Taiwan’s public disclosure system detailing the company's board composition, director terms, independent directors, vacancies, and committee setups (audit, remuneration) as well as governance-related information such as legal counsel and shareholder suggestion handling. This aligns with internal governance structure details rather than a report or announcement of financials, votes, or transactions. Therefore, it fits the “Governance Information” category (CGR).
2026-05-22 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個多 國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成澳洲主管 機關HREC送件
Regulatory Filings Classification · 88% confidence The document is a regulatory disclosure on a Taiwanese Market Observation Post System, detailing the company’s submission of a Phase III clinical trial application for a new drug. It contains no financial statements, earnings data, management changes, or voting results, and is clearly an announcement of a material event rather than a corporate report. It therefore falls under the general Regulatory Filings (RNS) category.
2026-05-20 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.